Novo Sues Lilly: Omits Wegovy’s 19% Weight Loss, Seeks Injunction

For in-house counsel and litigators tracking pharmaceutical advertising disputes, this lawsuit marks a critical test of Lanham Act claims in the competitive GLP-1 market. Novo’s argument hinges on whether “ineffective, fine-print disclaimers” can cure allegedly misleading comparisons when newer FDA-approved dosing data is available. The case could reshape how courts view comparative ad challenges in direct-to-consumer campaigns.

Novo Nordisk has escalated the intensely competitive GLP-1 receptor agonist market into the courtroom, filing a false advertising and unfair competition lawsuit against archrival Eli Lilly on July 21, 2026, in the U.S. District Court for the District of New Jersey. The suit, brought under the federal Lanham Act and state laws, targets Lilly’s high-profile direct-to-consumer television and digital advertising for its blockbuster drugs Zepbound (tirzepatide) for obesity and Mounjaro (tirzepatide) for type 2 diabetes.

“

Novo Nordisk’s U.S.-listed shares (NVO) closed at $49.61 on July 21, down 1.41%, near the lower end of its 52-week range of $35.12–$71.80, reflecting broader sector pressures but also wariness about the legal costs and uncertainty.

At the heart of the complaint is the allegation that Lilly’s nationwide campaigns rely on outdated or incomplete clinical comparisons that pit Lilly’s maximum doses against older, lower doses of Novo Nordisk’s competing GLP-1 products, while deliberately omitting data on Novo’s newly FDA-approved, higher-dose formulations. The most significant new offering is Wegovy 7.2 mg (semaglutide), which the FDA greenlit in March 2026. In the pivotal STEP UP trial, a 72-week study of 1,407 adults with obesity, Wegovy 7.2 mg delivered an average weight loss of approximately 19%—roughly 47 pounds—making it among the most effective anti-obesity medications on record. Novo contends that by excluding this clinical breakthrough in comparative ads that continue to be broadcast nationally, Lilly is materially misleading patients and prescribers about the relative efficacy landscape.

The complaint asserts that the allegedly deceptive ads cannot be cured by what Novo’s group general counsel John F. Kuckelman called “ineffective, fine-print disclaimers.” This argument touches on a recurrent tension in pharmaceutical advertising: where does the line fall between clever positioning and actionable falsehood when a competitor’s product evolves? The lawsuit requests a permanent injunction ordering Lilly to pull the ads, with a threat to seek a preliminary injunction shortly if Lilly does not voluntarily remove them.

The legal action underscores the ferocity of the GLP-1 market share battle. The combined obesity and diabetes markets for these agents are projected to exceed $100 billion annually by decade’s end, and advertising spending has soared into the hundreds of millions. Both companies are under immense pressure to defend and expand their franchises. Novo’s Wegovy and Ozempic (lower doses) have been mainstays, but Lilly’s Zepbound and Mounjaro have rapidly gained ground thanks to head-to-head trial advantages and aggressive direct-to-consumer promotion. Novo’s move to introduce a more potent Wegovy dose—and now to force Lilly’s ads to reflect it—is a strategic pivot to reclaim the narrative of superior efficacy.

From an investor perspective, the stock market reaction was immediate. Novo Nordisk’s U.S.-listed shares (NVO) closed at $49.61 on July 21, down 1.41%, near the lower end of its 52-week range of $35.12–$71.80, reflecting broader sector pressures but also wariness about the legal costs and uncertainty. Eli Lilly shares (LLY) will similarly face scrutiny as the litigation forces costly ad revisions and dent brand credibility.